You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

270 Results
Regimen
Cancer Type:
Skin, 
Basal Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
sonidegib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2021
Regimen
Cancer Type:
Hematologic, 
Amyloidosis
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab and Bortezomib in combo with Cyclophosphamide and Dexamethasone - Previously Untreated Light Chain (AL) Amyloidosis
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Daratumumab and Bortezomib in combo with Cyclophosphamide and Dexamethasone - Previously Untreated Light Chain (AL) Amyloidosis
ODB - General Benefit
    cyclophosphamide - oral tablets
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daratumumab (subcut),
cyclophosphamide,
bortezomib,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
ODB - General Benefit
    etoposide - oral capsules
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
prednisone,
vinCRIStine,
cyclophosphamide,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2021
Guidelines and Advice
Status: Current
ID: ES 30-1
Mar 2021
Cancer facts
May 2021
Cancer facts
May 2021
Guidelines and Advice
Status: Current
Jun 2021
Guidelines and Advice
Status: Current
Jun 2021
Guidelines and Advice
Status: Current
Jun 2021
Guidelines and Advice
Status: Current
Jun 2021
Guidelines and Advice
Status: Current
ID: PET 2020-2
May 2021
Guidelines and Advice
Status: Current
ID: GL 2-30B
May 2021

Pages